The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO WCGIC 2020 | PANGEA: personalized antibodies for gastroesophageal adenocarcinoma

Name: PANGEA: personalized antibodies for gastroesophageal adenocarcinoma
Uploaded: 2020-07-06T00:00:00Z
Duration: 5 min 42 s
Description: Daniel Catenacci, MD, of the University of Chicago, Chicago, IL, discusses the phase IIa PANGEA study (NCT02213289), a precision medicine trial in gastroesophageal adenocarcinoma, evaluating biomarkers for antibody therapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Daniel Catenacci • 6 Jul 2020

ESMO WCGIC 2020

Gastroesophageal Cancer Gastrointestinal Cancer

Daniel Catenacci, MD, of the University of Chicago, Chicago, IL, discusses the phase IIa PANGEA study (NCT02213289), a precision medicine trial in gastroesophageal adenocarcinoma, evaluating biomarkers for antibody therapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).